InflaRx and current shareholders placed $ 117,3 Mio. of shares, with $ 63 Mio. as primary shares with the proceeds going to InflaRx and $ 54 Mio. as secondary shares with the proceeds going to early shareholders, who all remain invested in InflaRx
The NASDAQ listed company, InflaRx NV (Nasdaq: IFRX) from Jena informed the markets of a primary and secondary share placement in total of $ 117,3 Mio. $ 63 Mio. worth of shares were sold as primary shares with the proceeds going to InflaRx and $ 54 Mio. worth of shares were sold by existing shareholders as secondary shares. All selling shareholders remain invested in InflaRx.
InflaRx develops therapies for the treatment of inflammation-related maladies, which target the complement system, a key component of the body´s natural immune system. InflaRx intends to use the proceeds from the capital raise to finance the further clinical development of its lead candidate IFX-1, which is currently in Phase IIb.
The therapy is being trialed on patients with moderate to advanced Hidradenitis Suppurativa (HS), which is a painful and chronic inflammatory skin disease with currently limited treatment options. Furthermore, the compound is going to be tested in two phase II trials for additional auto-immune and inflammation indications.
bm|t beteiligungsmanagement Thüringen GmbH is proud to have been the lead investor in InflaRx since day one.